Skip to main content
. Author manuscript; available in PMC: 2024 Jun 21.
Published in final edited form as: N Engl J Med. 2024 Jun 20;390(23):2143–2155. doi: 10.1056/NEJMoa2401532

Figure 2: Adverse Events.

Figure 2:

Depicted are all adverse events with an attribution of at least possibly related to ViPOR therapy and occurring in ≥20% of patients. Adverse events are depicted in descending order of frequency and broken down by grade of toxicity encountered.